Clinical and Economic Burden of Antineutrophil Cytoplasmic Antibody-associated XXXX in the United States.

@entity1 @entity1479 @entity1333 @entity3468 @entity6129 @entity2883
OBJECTIVE: To describe the prevalence of major relapse and healthcare costs among @entity1 with @entity2883 with @entity2883 (GPA); to find @entity1 with @entity6129 ( @entity6129 ) in administrative databases, because no @entity6129 diagnosis code exists; and to describe the clinical and economic burden associated with @entity6129 . METHODS: Adults (>=  18 yrs) with >=  2 diagnoses of GPA [International Classification of Diseases-9-Clinical Modification ( @entity1479 446.4)] during 2009-2013 were extracted from the Truven Health MarketScan Commercial and Medicare Supplemental databases. Evidence of major relapse (based on the Birmingham @entity1333 Activity Score) and healthcare costs were collected during 12-month and 24-month followup periods. Adults with >=  2 diagnoses of unspecified @entity3468 ( @entity1479 447.6) were found as potential @entity1 with @entity6129 and additional criteria based on clinical input were applied to refine the sample. Major relapse-associated conditions and healthcare costs in the 6 months pre- and post-diagnosis were measured. Costs were inflated to 2013 US . RESULTS: A total of 2784 @entity1 with GPA were found and 18.7% experienced a major relapse in the 12-month followup period. The @entity1 with a major relapse incurred higher average all-cause (12-month:  88,065 vs  30,682; p < 0.0001) and GPA-related costs (12-month:  61,636 vs  15,748; p < 0.0001) than @entity1 without a relapse. Trends were consistent over the 24-month followup period. There were 612 incident @entity1 with @entity6129 . Following @entity6129 diagnosis, healthcare costs nearly doubled ( 30,166 vs  56,642; p < 0.0001). CONCLUSION: In a real-world setting, @entity1 with GPA who experience major relapse have higher economic burden, compared to @entity1 without a relapse. @entity6129 diagnosis was associated with nearly a 2-fold increase in healthcare costs.
